Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients

E. Dvořáčková, M. Šíma, J. Petrus, E. Klapková, P. Hubáček, J. Pozniak, J. Havlín, R. Lischke, O. Slanař

. 2022 ; 14 (2) : . [pub] 20220213

Language English Country Switzerland

Document type Journal Article

Grant support
MH CZ-DRO (Motol University Hospital, Prague, Czech Republic 00064203) Ministry of Health
Cooperatio Program (research area PHAR) Charles University
SVV 260523 Charles University

The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients, to explore its covariates, and to propose an individualized dosing regimen. Ganciclovir was administered according to the protocol in a standardized intravenous dose of 5 mg/kg twice daily. Serum ganciclovir concentrations were monitored as a trough and at 3 and 5 h after dosing. Individual ganciclovir pharmacokinetic parameters were calculated in a two-compartmental pharmacokinetic model, while regression models were used to explore the covariates. Optimal loading and maintenance doses were calculated for each patient. In lung transplant recipients (n = 40), the median (IQR) ganciclovir total volume of distribution and clearance values were 0.65 (0.52-0.73) L/kg and 0.088 (0.059-0.118) L/h/kg, respectively. We observed medium-to-high inter-individual but negligible intra-individual variability in ganciclovir pharmacokinetics. The volume of distribution of ganciclovir was best predicted by height, while clearance was predicted by glomerular filtration rate. Bodyweight-normalized clearance was significantly higher in patients with cystic fibrosis, while distribution half-life was reduced in this subgroup. On the basis of the observed relationships, practical nomograms for individualized ganciclovir dosing were proposed. The dosing of ganciclovir in patients with cystic fibrosis requires special caution, as their daily maintenance dose should be increased by approximately 50%.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010021
003      
CZ-PrNML
005      
20220425131651.0
007      
ta
008      
220420s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics14020408 $2 doi
035    __
$a (PubMed)35214140
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dvořáčková, Eliška $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
245    10
$a Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients / $c E. Dvořáčková, M. Šíma, J. Petrus, E. Klapková, P. Hubáček, J. Pozniak, J. Havlín, R. Lischke, O. Slanař
520    9_
$a The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients, to explore its covariates, and to propose an individualized dosing regimen. Ganciclovir was administered according to the protocol in a standardized intravenous dose of 5 mg/kg twice daily. Serum ganciclovir concentrations were monitored as a trough and at 3 and 5 h after dosing. Individual ganciclovir pharmacokinetic parameters were calculated in a two-compartmental pharmacokinetic model, while regression models were used to explore the covariates. Optimal loading and maintenance doses were calculated for each patient. In lung transplant recipients (n = 40), the median (IQR) ganciclovir total volume of distribution and clearance values were 0.65 (0.52-0.73) L/kg and 0.088 (0.059-0.118) L/h/kg, respectively. We observed medium-to-high inter-individual but negligible intra-individual variability in ganciclovir pharmacokinetics. The volume of distribution of ganciclovir was best predicted by height, while clearance was predicted by glomerular filtration rate. Bodyweight-normalized clearance was significantly higher in patients with cystic fibrosis, while distribution half-life was reduced in this subgroup. On the basis of the observed relationships, practical nomograms for individualized ganciclovir dosing were proposed. The dosing of ganciclovir in patients with cystic fibrosis requires special caution, as their daily maintenance dose should be increased by approximately 50%.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/000000026541738X $7 xx0222901
700    1_
$a Petrus, Jakub $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Klapková, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Hubáček, Petr $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Pozniak, Jiří $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Havlín, Jan $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic $1 https://orcid.org/0000000276672634 $7 xx0093656
700    1_
$a Lischke, Robert $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000253577562 $7 xx0058262
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 2 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35214140 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131649 $b ABA008
999    __
$a ind $b bmc $g 1784466 $s 1161219
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 2 $e 20220213 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a MH CZ-DRO (Motol University Hospital, Prague, Czech Republic 00064203) $p Ministry of Health
GRA    __
$a Cooperatio Program (research area PHAR) $p Charles University
GRA    __
$a SVV 260523 $p Charles University
LZP    __
$a Pubmed-20220420

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...